Deutsche Bank AG Boosts Stock Holdings in The Chemours Company (NYSE:CC)

Deutsche Bank AG grew its stake in shares of The Chemours Company (NYSE:CC - Free Report) by 74.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 86,029 shares of the specialty chemicals company's stock after purchasing an additional 36,823 shares during the quarter. Deutsche Bank AG owned approximately 0.06% of Chemours worth $1,454,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Norges Bank purchased a new stake in shares of Chemours during the fourth quarter worth about $30,702,000. Bank of Montreal Can grew its position in shares of Chemours by 1,496.4% in the 4th quarter. Bank of Montreal Can now owns 953,240 shares of the specialty chemicals company's stock valued at $16,110,000 after buying an additional 893,530 shares during the last quarter. Ameriprise Financial Inc. grew its position in shares of Chemours by 23.8% during the fourth quarter. Ameriprise Financial Inc. now owns 4,373,172 shares of the specialty chemicals company's stock worth $73,907,000 after acquiring an additional 839,849 shares during the last quarter. Invesco Ltd. grew its stake in shares of Chemours by 141.5% in the 4th quarter. Invesco Ltd. now owns 1,020,001 shares of the specialty chemicals company's stock valued at $17,238,000 after purchasing an additional 597,638 shares during the last quarter. Finally, Covalis Capital LLP purchased a new stake in Chemours in the 4th quarter valued at approximately $8,768,000. Institutional investors own 76.26% of the company's stock.

Chemours Stock Performance

Shares of CC traded up $0.11 during mid-day trading on Thursday, hitting $10.12. The company's stock had a trading volume of 4,521,080 shares, compared to its average volume of 2,123,951. The Chemours Company has a one year low of $9.33 and a one year high of $25.98. The firm has a market capitalization of $1.51 billion, a PE ratio of 17.75 and a beta of 1.76. The stock's 50-day moving average is $11.63 and its two-hundred day moving average is $15.74. The company has a debt-to-equity ratio of 6.70, a quick ratio of 0.92 and a current ratio of 1.68.

Chemours (NYSE:CC - Get Free Report) last posted its earnings results on Tuesday, May 6th. The specialty chemicals company reported $0.13 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.19 by ($0.06). Chemours had a net margin of 1.51% and a return on equity of 26.54%. The firm had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.36 billion. During the same quarter last year, the firm posted $0.32 EPS. The business's revenue was up .4% on a year-over-year basis. As a group, sell-side analysts anticipate that The Chemours Company will post 2.03 EPS for the current year.

Chemours Announces Dividend

The company also recently disclosed a dividend, which will be paid on Monday, June 16th. Investors of record on Monday, May 19th will be issued a dividend of $0.0875 per share. The ex-dividend date is Friday, May 16th. This represents a dividend yield of 3.17%. Chemours's payout ratio is presently 175.00%.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on CC shares. UBS Group reduced their price objective on shares of Chemours from $18.00 to $17.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Mizuho set a $15.00 target price on shares of Chemours in a report on Tuesday, April 15th. Truist Financial cut their price objective on shares of Chemours from $27.00 to $22.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. Royal Bank of Canada decreased their price target on shares of Chemours from $17.00 to $14.00 and set an "outperform" rating on the stock in a research report on Thursday, May 8th. Finally, Morgan Stanley reduced their price objective on Chemours from $22.00 to $15.00 and set an "equal weight" rating for the company in a research note on Monday, May 12th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Chemours currently has an average rating of "Hold" and a consensus target price of $17.22.

Insider Transactions at Chemours

In related news, CFO Shane Hostetter purchased 4,450 shares of the stock in a transaction on Monday, May 19th. The shares were purchased at an average cost of $11.28 per share, with a total value of $50,196.00. Following the acquisition, the chief financial officer now directly owns 59,694 shares in the company, valued at $673,348.32. The trade was a 8.06% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 0.34% of the stock is currently owned by insiders.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.